EA008835B1 - Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы - Google Patents

Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы Download PDF

Info

Publication number
EA008835B1
EA008835B1 EA200500054A EA200500054A EA008835B1 EA 008835 B1 EA008835 B1 EA 008835B1 EA 200500054 A EA200500054 A EA 200500054A EA 200500054 A EA200500054 A EA 200500054A EA 008835 B1 EA008835 B1 EA 008835B1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrochloride
piperazin
tert
mmol
sulfonyl
Prior art date
Application number
EA200500054A
Other languages
English (en)
Russian (ru)
Other versions
EA200500054A1 (ru
Inventor
Гари Йоханссон
Анника Йенмальм-Йенсен
Катарина Бейерлейн
Original Assignee
Биовитрум Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/xx
Priority claimed from SE0202181A external-priority patent/SE0202181D0/xx
Priority claimed from SE0202908A external-priority patent/SE0202908D0/xx
Priority claimed from SE0300357A external-priority patent/SE0300357D0/xx
Application filed by Биовитрум Аб filed Critical Биовитрум Аб
Publication of EA200500054A1 publication Critical patent/EA200500054A1/ru
Publication of EA008835B1 publication Critical patent/EA008835B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA200500054A 2002-06-20 2003-06-19 Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы EA008835B1 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (sv) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (sv) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (sv) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (sv) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (2)

Publication Number Publication Date
EA200500054A1 EA200500054A1 (ru) 2005-06-30
EA008835B1 true EA008835B1 (ru) 2007-08-31

Family

ID=30004107

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200600975A EA011581B1 (ru) 2002-06-20 2003-06-19 Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы
EA200500054A EA008835B1 (ru) 2002-06-20 2003-06-19 Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200600975A EA011581B1 (ru) 2002-06-20 2003-06-19 Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы

Country Status (13)

Country Link
EP (1) EP1513828A1 (sr)
CN (1) CN1662521A (sr)
AU (1) AU2003243091A1 (sr)
BR (1) BR0311952A (sr)
CA (1) CA2486989A1 (sr)
EA (2) EA011581B1 (sr)
IL (1) IL165051A0 (sr)
MX (1) MXPA04012914A (sr)
NO (1) NO20050294L (sr)
NZ (3) NZ536600A (sr)
RS (1) RS111204A (sr)
SG (1) SG156524A1 (sr)
WO (1) WO2004000828A1 (sr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307919T3 (es) 2002-03-27 2008-12-01 Glaxo Group Limited Derivados de quinolina y su uso como ligandos de 5-ht6.
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
BRPI0417833A (pt) * 2003-12-19 2007-04-17 Biovitrum Ab novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
TWI380816B (zh) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-12(il-12)生成之二鹽抑制劑
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (es) * 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
KR20140033237A (ko) 2005-10-07 2014-03-17 엑셀리시스, 인코포레이티드 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
CA2654822A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
CN101472884A (zh) 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
JP2009541248A (ja) 2006-06-20 2009-11-26 エフ.ホフマン−ラ ロシュ アーゲー アリールスルホンアミジルテトラリン誘導体及びそれらの使用
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2012154194A1 (en) * 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
WO1994021619A1 (en) * 1993-03-16 1994-09-29 Pfizer Inc. Naphthalene derivatives
EP0701819A2 (en) * 1994-09-14 1996-03-20 Pfizer Inc. Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO2000012073A1 (en) * 1998-08-28 2000-03-09 Smithkline Beecham P.L.C. Use of 5ht-6 antagonists
WO2000055159A2 (en) * 1999-03-04 2000-09-21 Glaxo Group Limited Substituted aza-oxindole derivatives
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001032646A2 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Sulfonamide derivatives
WO2001085722A1 (en) * 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
WO2001096336A2 (en) * 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002092585A1 (en) * 2001-05-11 2002-11-21 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
WO2002098857A1 (en) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
WO1994021619A1 (en) * 1993-03-16 1994-09-29 Pfizer Inc. Naphthalene derivatives
EP0701819A2 (en) * 1994-09-14 1996-03-20 Pfizer Inc. Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO2000012073A1 (en) * 1998-08-28 2000-03-09 Smithkline Beecham P.L.C. Use of 5ht-6 antagonists
WO2000055159A2 (en) * 1999-03-04 2000-09-21 Glaxo Group Limited Substituted aza-oxindole derivatives
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001032646A2 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Sulfonamide derivatives
WO2001085722A1 (en) * 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
WO2001096336A2 (en) * 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002092585A1 (en) * 2001-05-11 2002-11-21 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
WO2002098857A1 (en) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, vol. 10, No. 15, 2000, Methvin Isaac et al.: "6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-Bicyclopiperidinyl-1-arylsulfonylindoles Derivatives as Novel, Potent, and Selective 5-HT6 Receptor Antagonists", page 1719 - page 1721, compound 3 *

Also Published As

Publication number Publication date
AU2003243091A1 (en) 2004-01-06
BR0311952A (pt) 2005-04-19
EA200500054A1 (ru) 2005-06-30
EA200600975A1 (ru) 2006-10-27
CA2486989A1 (en) 2003-12-31
NZ536600A (en) 2007-08-31
WO2004000828A1 (en) 2003-12-31
NZ552283A (en) 2008-07-31
IL165051A0 (en) 2005-12-18
MXPA04012914A (es) 2005-03-31
NZ552282A (en) 2008-07-31
EA011581B1 (ru) 2009-04-28
CN1662521A (zh) 2005-08-31
RS111204A (en) 2006-12-15
SG156524A1 (en) 2009-11-26
NO20050294L (no) 2005-02-04
EP1513828A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
EA008835B1 (ru) Замещенные сульфоны и сульфонамиды и фармацевтические композиции на их основе, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы
US7943639B2 (en) Compounds
JP3989444B2 (ja) 新規な化合物
JP5291095B2 (ja) イミダゾピリジンキナーゼ阻害剤
CN105209468B (zh) 取代的7‑氮杂二环化合物以及它们作为食欲素受体调节剂的用途
JP5501226B2 (ja) アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤
US20210230116A1 (en) 1,4-Substituted Piperidine Derivatives
RU2257384C2 (ru) Новые производные циклического амида
JP5957077B2 (ja) タンキラーゼ阻害剤として使用するための4−ピペリジニル化合物
TWI796205B (zh) 新穎cyp11a1抑制劑
EA008476B1 (ru) Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii
WO2002032872A1 (en) Nitrogenous aromatic ring compounds
EA013250B1 (ru) Ингибиторы c-fms киназы
EA016128B1 (ru) Производные тиенопиридина как ингибиторы мек
KR20080080395A (ko) 항바이러스 화합물
JP2014520858A (ja) タンキラーゼ阻害剤として用いるための新規な2−ピペリジン−1−イル−アセトアミド化合物
MXPA06012894A (es) Compuestos amido y sus usos como farmaceuticos.
KR20090092832A (ko) 비만, 제 ⅱ 형 당뇨병 및 cns 장애의 치료를 위한 신규한 아릴술폰아미드 화합물
TW200815412A (en) A pharmaceutical combination comprising 3-or 4-monosubstituted phenol and thiophenol derivatives
EA015555B1 (ru) Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора
EA010298B1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
CA3201443A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
TW202134213A (zh) 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
CN106458902B (zh) 吡啶衍生物
JP2002201193A (ja) 三環性化合物、その製造法および剤

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU